Oxford Biomedica PLC License & Supply Agreement with Juno Therapeutics (5429G)
18 March 2020 - 6:00PM
UK Regulatory
TIDMOXB
RNS Number : 5429G
Oxford Biomedica PLC
18 March 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Oxford Biomedica Signs License & Clinical Supply Agreement
with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for
LentiVector(R) Platform for CAR-T and TCR-T Therapeutics
Oxford, UK - 18 March 2020: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, announced today that it has signed a new Licence and
Clinical Supply Agreement ("LSA") with Juno Therapeutics, a
Bristol-Myers Squibb company (NYSE: BMY). The LSA grants Juno
Therapeutics a non-exclusive license to Oxford Biomedica's
LentiVector(R) platform for its application in CAR-T and TCR-T
programmes in oncology and other indications, and additionally puts
in place a five year Clinical Supply Agreement, which may be
extended further.
Under the terms of the LSA, Oxford Biomedica will receive an
upfront payment of $10 million in cash and potentially up to $86
million upon achievement of certain development and regulatory
milestones related to multiple products and indications. Oxford
Biomedica is also entitled to receive up to $131 million in
sales-based milestone payments and an undisclosed royalty on the
net sales of products sold by Juno Therapeutics utilising the
LentiVector(R) platform. Oxford Biomedica will also receive
payments from process development and scale-up projects as well as
relating to the GMP manufacture of lentiviral vectors for use in
clinical trials.
As part of the LSA, Juno Therapeutics will have access to Oxford
Biomedica's new 7,800 m(2) commercial manufacturing centre OxBox,
in Oxford, UK. Oxford Biomedica is already working on four
undisclosed active projects, with Juno able to initiate additional
projects in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
" Juno Therapeutics, a Bristol-Myers Squibb company, is a
recognised leader with an innovative pipeline in the CAR-T and
TCR-T field and we are delighted to sign this new agreement with
them. This new relationship with a long established leader in the
CAR-T field, underlines the value of Oxford Biomedica's
LentiVector(R) platform for leading companies. By offering world
leading lentiviral vector technologies and proven clinical and
commercial manufacturing capabilities, we are able to offer our
partners and customers a unique suite of capabilities not found
elsewhere in the industry.
"This is the second company that has committed to working with
us in our new OxBox facility, which we expect to be producing GMP
vector by the end of the first half 2020. Today's announcement
further validates our decision taken in 2018 to invest in and scale
up our GMP manufacturing facilities for clinical and commercial
viral vector manufacture to support both existing and new partners
and customers as well as the expected demand from industry."
-Ends-
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 480 people. Further information is available at
www.oxb.com
About OxBox
OxBox is Oxford Biomedica's new 7,800 m(2) commercial
manufacturing centre, located in Oxford, UK. Phase I, which will be
operational in 2020, is 4,200 m(2) of developed area consisting of
six GMP clean room suites - four for vector production and two for
fill-finish, warehousing and cold chain facilities and support
laboratories. Phase II will provide for flexible expansion for a
further six GMP clean room suites. This world class facility is
expected to more than double Oxford Biomedica's manufacturing
capacity, supporting further growth in revenues.
The person who arranged for the release of this announcement on
behalf of Oxford Biomedica plc was John Dawson, Chief Executive
Officer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRJRMTTMTIBTPM
(END) Dow Jones Newswires
March 18, 2020 03:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024